173 related articles for article (PubMed ID: 12923828)
1. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Morishita S; Arita S
Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
Morishita S; Arita S
Hum Psychopharmacol; 2004 Aug; 19(6):405-8. PubMed ID: 15303244
[TBL] [Abstract][Full Text] [Related]
3. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
5. Induction of mania in depression by paroxetine.
Morishita S; Arita S
Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
[TBL] [Abstract][Full Text] [Related]
6. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
Ikenouchi-Sugita A; Yoshimura R; Hori H; Umene-Nakano W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1451-3. PubMed ID: 19664676
[TBL] [Abstract][Full Text] [Related]
7. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Clerc G;
Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Lopez-Ibor JJ; Conesa A;
Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
[TBL] [Abstract][Full Text] [Related]
10. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
[TBL] [Abstract][Full Text] [Related]
11. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
12. Suitable dose and duration of fluvoxamine administration to treat depression.
Morishita S; Arita S
Psychiatry Clin Neurosci; 2003 Apr; 57(2):177-81. PubMed ID: 12667164
[TBL] [Abstract][Full Text] [Related]
13. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran.
Baldwin D; Moreno RA; Briley M
Hum Psychopharmacol; 2008 Aug; 23(6):527-32. PubMed ID: 18536065
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
Kato M; Serretti A; Nonen S; Takekita Y; Wakeno M; Azuma J; Kinoshita T
Transl Psychiatry; 2015 Feb; 5(2):e513. PubMed ID: 25710119
[TBL] [Abstract][Full Text] [Related]
16. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant response in the elderly.
Mandelli L; Serretti A; Zanardi R; Rossini D; De Ronchi D; Tarricone I; Colombo C
Psychiatry Res; 2007 Jul; 152(1):37-44. PubMed ID: 17383015
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
Morishita S; Arita S
Eur Psychiatry; 2004 Nov; 19(7):450-1. PubMed ID: 15504656
[No Abstract] [Full Text] [Related]
19. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of milnacipran and paroxetine in outpatients with major depression.
Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
